Scarica l'app Stockscreener
12.58
0.64%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.50
Aprire:
$12.48
Volume 24 ore:
3.15M
Relative Volume:
2.58
Capitalizzazione di mercato:
$718.13M
Reddito:
-
Utile/perdita netta:
$-72.89M
Rapporto P/E:
-5.1983
EPS:
-2.42
Flusso di cassa netto:
$-68.47M
1 W Prestazione:
+0.88%
1M Prestazione:
-2.48%
6M Prestazione:
+88.32%
1 anno Prestazione:
+66.62%
Intervallo 1D:
$12.45
$12.59
Intervallo di 1 settimana:
$12.24
$12.59
Portata 52W:
$3.555
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
Nome
Astria Therapeutics Inc
Settore
Industria
Telefono
617-349-1971
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta ATXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
12.58 | 718.13M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-29 | Iniziato | TD Cowen | Buy |
| 2023-03-28 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
New HAE shot every 3–6 months? BioCryst’s $700M bet on Astria - Stock Titan
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Hedge Fund Bets: Is Astria Therapeutics Inc trading at a discount2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Why (ATXS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - Yahoo Finance
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® - GlobeNewswire
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - Yahoo Finance
Why Astria Therapeutics Inc. stock could outperform in 20252025 Major Catalysts & Free Long-Term Investment Growth Plans - ulpravda.ru
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - sharewise.com
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - PR Newswire
Growth Recap: Is Astria Therapeutics Inc stock in correction or buying zone2025 Trade Ideas & Consistent Profit Focused Trading Strategies - Bộ Nội Vụ
Understanding Momentum Shifts in (ATXS) - Stock Traders Daily
Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - MSN
JMP Securities Downgrades Astria Therapeutics (ATXS) - MSN
Patterns Watch: Is Astria Therapeutics Inc stock gaining market shareMarket Performance Summary & Capital Efficiency Focused Strategies - moha.gov.vn
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment - MSN
(ATXS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks
Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve
Why Astria Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Reactions & Accurate Entry/Exit Alerts - DonanımHaber
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR - Sahm
Astria Therapeutics Earnings Notes - Trefis
Astria Therapeutics (ATXS) price target decreased by 17.94% to 21.62 - MSN
Technical Reactions to ATXS Trends in Macro Strategies - Stock Traders Daily
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com UK
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com
Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS - MarketBeat
Affinity Asset Advisors LLC Purchases Shares of 300,000 Astria Therapeutics, Inc. $ATXS - MarketBeat
Will Astria Therapeutics Inc. stock gain from government policies2025 Market Overview & Verified Swing Trading Watchlists - Newser
Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts - MarketBeat
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
Astria Therapeutics (NASDAQ:ATXS) Sets New 1-Year HighWhat's Next? - MarketBeat
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
BioCryst receives antitrust clearance for Astria acquisition - Investing.com
Astria Therapeutics Inc Azioni (ATXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):